![Jeffrey Feike](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffrey Feike
Keine laufenden Positionen mehr
Vermögen: 470 071 $ am 31.05.2024
Aktive Positionen von Jeffrey Feike
Unternehmen | Position | Beginn | Ende |
---|
Karriereverlauf von Jeffrey Feike
Ehemalige bekannte Positionen von Jeffrey Feike
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Direktor/Vorstandsmitglied | 17.08.2022 | - |
Corporate Officer/Principal | 17.08.2022 | - |
Ausbildung von Jeffrey Feike
Tulane University (Louisiana) | Graduate Degree |
Statistik
International
Vereinigte Staaten | 3 |
Operativ
Director/Board Member | 2 |
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Health Technology |
- Börse
- Insiders
- Jeffrey Feike
- Erfahrung